NCM
SLN

Nantahala Capital Management’s Silence Therapeutics SLN Stock Holding History

Nantahala Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Buy
2,146,731
+604,304
+39% +$3.33M 0.42% 64
2025
Q4 		$9.38M Buy
1,542,427
+500,000
+48% +$3.2M 0.31% 75
2025
Q3 		$5.41M Hold
1,042,427
– – 0.19% 103
2025
Q2 		$6.05M Hold
1,042,427
– – 0.24% 81
2025
Q1 		$2.94M Sell
1,042,427
-7,249
-0.7% -$35.4K 0.12% 99
2024
Q4 		$7.22M Buy
1,049,676
+849,676
+425% +$11M 0.31% 60
2024
Q3 		$3.64M Hold
200,000
– – 0.18% 83
2024
Q2 		$3.8M Hold
200,000
– – 0.22% 75
2024
Q1 		$4.32M Buy
+200,000
New +$4.35M 0.25% 69

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Nantahala Capital Management's SLN Position: Q1 2026 in Review

Nantahala Capital Management increased its Silence Therapeutics (SLN) stake by 39% in Q1 2026, buying an estimated $3.33M and bringing the position to 2,146,731 shares worth $11.3M. The position accounts for 0.42% of the portfolio, ranked #64.

Nantahala Capital Management first reported a position in SLN in Q1 2024 and has held it in 9 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Nantahala Capital Management held 2,146,731 shares of Silence Therapeutics worth $11.3M as of Q1 2026.
  • Nantahala Capital Management bought 604,304 Silence Therapeutics shares in Q1 2026, an estimated $3.33M.
  • Silence Therapeutics made up 0.42% of Nantahala Capital Management's portfolio in Q1 2026, its #64 holding.
  • Nantahala Capital Management first reported a position in Silence Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.